Sign inJoin waitlistJoin the waitlist

Lowell Anthony

Chief, Division of Medical Oncology – Department of Internal Medicine · University of Kentucky College of Medicine

Credentials: · · · · · ·

History

Division of Medical Oncology – Department of Internal Medicine · University of Kentucky College of Medicine
Present
Internal Medicine Division · University of Kentucky College of Medicine
Present
University of Kentucky College of Medicine
Present

Vanderbilt University
1982–1984
Internal Medicine
Vanderbilt University Medical Center
1979–1982
Vanderbilt University School of Medicine
1975–1979

Research

Consensus guidelines for the management and treatment of neuroendocrine tumors
Pancreas · 2013 · 440 citations
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas
Pancreas · 2010 · 411 citations
Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome
Journal of Clinical Oncology · 1999 · Last of 9 authors · 295 citations

Aman Chauhan
25 papers · 1 as a fellow
EW
Eugene Woltering
21 papers
Philip Boudreaux
14 papers
Susanne Arnold
14 papers
Mark Evers
13 papers
TO
Thomas O’Dorisio
12 papers
YW
Yi-Zarn Wang
11 papers
Matthew Kulke
10 papers
KH
Kenneth Hande
9 papers
PL
Pablo Lapuerta
8 papers
Emily Bergsland
7 papers
Pamela Kunz
6 papers

Grants

University of Kentucky Markey Cancer Center – Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $838.5K · University of Kentucky
2013–2028
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $108.9K · Tulane University of Louisiana
1997–2006
Routes of Ifosfamide Metabolism
National Cancer Institute · R29
Contact PI · $492.8K · Lsu Health Sciences Center
1992–1998
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $124K · Vanderbilt University
1997

Clinical trials

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2023–2026
Telotristat With Lutathera in Neuroendocrine Tumors
Principal investigator · Terminated · Phase 2
Lowell Anthony, MD
2021–2022
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2021–2026
Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs
Principal investigator · Completed · Phase 2
Lowell Anthony, MD
2018–2021